auxilium pharmaceuticals inc
(AUXL:NASDAQ GS)
auxilium pharmaceuticals inc (AUXL) Snapshot
|
Open
$15.21
|
Previous Close
$15.26
|
|
|
Day High
$15.70
|
Day Low
$15.05
|
|
|
52 Week High
07/31/12 - $29.37
|
52 Week Low
04/29/13 - $13.87
|
|
|
Market Cap
748.5M
|
Average Volume 10 Days
769.1K
|
|
|
EPS TTM
$1.61
|
Shares Outstanding
49.3M
|
|
|
EX-Date
--
|
P/E TM
9.4x
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
auxilium pharmaceuticals inc (AUXL) Related Businessweek News
No Related Businessweek News Foundauxilium pharmaceuticals inc (AUXL) Details
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products worldwide. It markets Testim, a topical 1% testosterone once-a-day gel for the treatment of hypogonadism; and XIAFLEX, an injectable clostridial collagenase enzyme for the treatment of Dupuytren’s in adult patients with a palpable cord. The company is also developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronie’s disease; and in Phase II clinical trial for the treatment of Adhesive Capsulitis, as well as in Phase II clinical trial for the treatment of edematous fibrosclerotic panniculopathy. In addition, it is developing a high concentration testosterone gel product. Further, the company has rights to pursue additional indications for collagenase clostridium histolyticum. Auxilium Pharmaceuticals, Inc. sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.
auxilium pharmaceuticals inc (AUXL) Top Compensated Officers
auxilium pharmaceuticals inc (AUXL) Key Developments
Auxilium Pharmaceuticals Inc. Presents at UBS Global Healthcare Conference, May-21-2013 03:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Adrian Adams, Chief Executive Officer, President and Director.
Auxilium Pharmaceuticals Inc. announced unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net revenues of $66.2 million. Loss from operations was $5.1 million against $1.9 million a year ago. Net loss was $8.2 million against $1.7 million a year ago. Basic and diluted loss per share was $0.17 against $0.04 a year ago. On Non-GAAP basis, net revenue of $73.6 million. Loss from operations was $1.4 million against income form operations of $1.7 million a year ago. Net loss was $2.3 million against net income of $1.9 million a year ago. Basic and diluted loss per share was $0.05 against basic and diluted earnings per share of $0.04 a year ago. The decrease in net Revenue was due to decreases in U.S. sales of XIAFLEX and Testim.
Auxilium Pharmaceuticals Inc., Q1 2013 Earnings Call, Apr 29, 2013
| Recently Viewed | |||
| AUXL:US | $15.18 USD | -0.08 |  |
| Company | Last | Change |
| AbbVie Inc | $45.44 USD | -1.15 |
| Acrux Ltd | A$3.81 AUD | -0.04 |
| Actavis Inc | $127.23 USD | -0.85 |
| Antares Pharma Inc | $4.11 USD | +0.06 |
| Mylan Inc/PA | $31.18 USD | -0.57 |
| View Industry Companies | ||
Industry Analysis
AUXL
Industry Average
| Valuation | AUXL | Industry Range |
| Price/Earnings | 9.5x |
|
| Price/Sales | 1.9x |
|
| Price/Book | 3.2x |
|
| Price/Cash Flow | 9.5x |
|
| TEV/Sales | NM | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact AUXILIUM PHARMACEUTICALS INC, please visit www.auxilium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
